![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Approves First New Sickle Cell Drug in 20 Years
FDA Approves First New Sickle Cell Drug in 20 Years
![FDA_Logo_Black_2016.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA_Logo_Black_2016.gif?t=1579040596&width=430)
July 10, 2017
The FDA on Friday approved Endari, the first new drug in nearly 20 years to treat sickle cell anemia complications.
The L-glutamine oral powder, sponsored by Emmaus Medical, was approved for adults and children over 5 years old to reduce severe complications associated with the blood disorder. Previously, the only available treatment was hydroxyurea, approved by the FDA in 1998.
Though glutamine is currently sold as a nutritional supplement and a medical food, Emmaus’ L-glutamine will be produced and sold as a prescription drug.
Upcoming Events
-
21Oct